JP2019534884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534884A5 JP2019534884A5 JP2019519252A JP2019519252A JP2019534884A5 JP 2019534884 A5 JP2019534884 A5 JP 2019534884A5 JP 2019519252 A JP2019519252 A JP 2019519252A JP 2019519252 A JP2019519252 A JP 2019519252A JP 2019534884 A5 JP2019534884 A5 JP 2019534884A5
- Authority
- JP
- Japan
- Prior art keywords
- antigenic peptide
- nucleic acid
- amino acid
- immunogenic
- immunogenic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 15
- 230000000890 antigenic Effects 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000002105 nanoparticle Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 229920002676 Complementary DNA Polymers 0.000 claims 1
- 108020004394 Complementary RNA Proteins 0.000 claims 1
- 229960001438 IMMUNOSTIMULANTS Drugs 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 229920002847 antisense RNA Polymers 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000003344 immunostimulant Effects 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 229920002973 ribosomal RNA Polymers 0.000 claims 1
- 229920002033 ribozyme Polymers 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
Claims (15)
- 配列番号１０１、１０２、及び１０２のいずれかで表されるアミノ酸配列を含む又はからなる抗原性ペプチドを含むことを特徴とする免疫原性化合物。
- 前記抗原性ペプチドが、担体タンパク質に結合される請求項１に記載の免疫原性化合物。
- 以下の式（Ｉ）の抗原性ペプチドを含む又はからなる請求項１から２のいずれかに記載の免疫原性化合物：
ＰｅｐＮｔ−ＣＯＲＥ−ＰｅｐＣｔ （Ｉ） 式中、
−「ＰｅｐＮｔ」は、０〜５００のアミノ酸残基のアミノ酸長を有するポリペプチドからなり、式（Ｉ）のポリペプチドのＮ末端に位置し；
−ＣＯＲＥは、配列番号１００〜１０２からなる群から選択されるアミノ酸配列を含む又はからなるポリペプチドからなり；及び
−「ＰｅｐＣｔ」は、０〜５００のアミノ酸残基のアミノ酸長を有するポリペプチドからなり、式（Ｉ）のポリペプチドのＣ末端に位置する。 - 配列番号１００、１０１、及び１０２のいずれかで表されるアミノ酸配列を含む又はからなることを特徴とする抗原性ペプチド。
- −請求項１から３のいずれかに記載の免疫原性化合物の少なくとも１つ、又は
−請求項４に記載の抗原性ペプチドの少なくとも１つ；及び
任意にアジュバントがロードされたことを特徴とするナノ粒子。 - 請求項１から３のいずれかに記載の免疫原性化合物、又は請求項４に記載の抗原性ペプチドがロードされたことを特徴とする細胞。
- 以下をコードするポリヌクレオチドを含むことを特徴とする核酸：
−ペプチド又はタンパク質である、請求項１から３のいずれかに記載の免疫原性化合物；又は
−請求項４に記載の抗原性ペプチド。 - 前記核酸が、ＤＮＡ分子又はＲＮＡ分子であり、好ましくは、ゲノムＤＮＡ；ｃＤＮＡ；ｓｉＲＮＡ；ｒＲＮＡ；ｍＲＮＡ；アンチセンスＤＮＡ；アンチセンスＲＮＡ；リボザイム；相補的ＲＮＡ及び／又はＤＮＡ配列；発現エレメント、調節エレメント、及び／又はプロモーターを含む又は含まないＲＮＡ及び／又はＤＮＡ配列；ベクター；それらの組合せから選択される請求項７に記載の核酸。
- 請求項７から８のいずれかに記載の核酸を含む宿主細胞であって、前記核酸が、好ましくはベクターであることを特徴とする宿主細胞。
- −請求項１から３のいずれかに記載の免疫原性化合物、
−請求項４に記載の抗原性ペプチド、
−請求項５に記載のナノ粒子、
−請求項６に記載の細胞、
−請求項７から８のいずれかに記載の核酸、又は
−請求項９に記載の宿主細胞、及び
１以上の薬学的に許容される賦形剤を含むことを特徴とする免疫原性組成物。 - １以上の免疫刺激剤を更に含む請求項１０に記載の免疫原性組成物。
- 薬としての使用のための、請求項１から３のいずれかに記載の免疫原性化合物、請求項４に記載の抗原性ペプチド、請求項５に記載のナノ粒子、請求項６に記載の細胞、請求項７から８のいずれかに記載の核酸、請求項９に記載の宿主細胞、又は請求項１０から１１のいずれかに記載の免疫原性組成物。
- 癌の予防又は治療における使用のための、請求項１から３のいずれかに記載の免疫原性化合物、請求項４に記載の抗原性ペプチド、請求項５に記載のナノ粒子、請求項６に記載の細胞、請求項７から８のいずれかに記載の核酸、請求項９に記載の宿主細胞、又は請求項１０から１１のいずれかに記載の免疫原性組成物。
- 請求項４に記載の抗原性ペプチドを含む少なくとも２つの異なる抗原性ペプチドと、配列番号１から１０６のいずれかで表されるアミノ酸配列を含む又はからなる少なくとも１つの抗原性ペプチドとの組合せ。
- −請求項１から３のいずれかに記載の免疫原性化合物、
−請求項４に記載の抗原性ペプチド、
−請求項５に記載のナノ粒子、
−請求項６に記載の細胞、
−請求項７から８のいずれかに記載の核酸、
−請求項９に記載の宿主細胞、又は
−請求項１０から１１のいずれかに記載の免疫原性組成物を含むことを特徴するキット。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096260A JP7331207B2 (ja) | 2016-10-07 | 2022-06-15 | 癌治療のための免疫原性化合物 |
| JP2023129666A JP2023156414A (ja) | 2016-10-07 | 2023-08-09 | 癌治療のための免疫原性化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16192948.4 | 2016-10-07 | ||
| EP16192948 | 2016-10-07 | ||
| PCT/EP2017/075673 WO2018065623A2 (en) | 2016-10-07 | 2017-10-09 | Immunogenic compounds for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096260A Division JP7331207B2 (ja) | 2016-10-07 | 2022-06-15 | 癌治療のための免疫原性化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534884A JP2019534884A (ja) | 2019-12-05 |
| JP2019534884A5 true JP2019534884A5 (ja) | 2020-11-19 |
| JP7116278B2 JP7116278B2 (ja) | 2022-08-10 |
Family
ID=57123864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519252A Active JP7116278B2 (ja) | 2016-10-07 | 2017-10-09 | 癌治療のための免疫原性化合物 |
| JP2022096260A Active JP7331207B2 (ja) | 2016-10-07 | 2022-06-15 | 癌治療のための免疫原性化合物 |
| JP2023129666A Pending JP2023156414A (ja) | 2016-10-07 | 2023-08-09 | 癌治療のための免疫原性化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096260A Active JP7331207B2 (ja) | 2016-10-07 | 2022-06-15 | 癌治療のための免疫原性化合物 |
| JP2023129666A Pending JP2023156414A (ja) | 2016-10-07 | 2023-08-09 | 癌治療のための免疫原性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11478537B2 (ja) |
| EP (1) | EP3522915A2 (ja) |
| JP (3) | JP7116278B2 (ja) |
| KR (2) | KR20240007316A (ja) |
| CN (2) | CN110022893B (ja) |
| AU (3) | AU2017339577B2 (ja) |
| CA (1) | CA3039322A1 (ja) |
| IL (3) | IL296165B2 (ja) |
| WO (1) | WO2018065623A2 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5550214A (en) * | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| CA2365296A1 (en) | 1999-03-19 | 2000-09-28 | Pierre Michel Desmons | Vaccine |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| EP1917970B1 (en) * | 1999-06-29 | 2011-06-15 | Epimmune Inc. | Hla binding peptides and their uses |
| CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| JP2003524016A (ja) | 2000-02-23 | 2003-08-12 | エピミューン， インコーポレイテッド | Ｈｌａ結合ペプチドおよびそれらの用途 |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| CA2480008C (en) | 2002-03-22 | 2015-10-06 | The Penn State Research Foundation | Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine |
| EP1578432A4 (en) * | 2002-10-03 | 2008-07-30 | Epimmune Inc | HLA BINDING PEPTIDES AND USES THEREOF |
| CA2558733C (en) * | 2004-02-06 | 2016-04-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| EP4032899A1 (en) | 2007-08-20 | 2022-07-27 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
| US20110182926A1 (en) | 2008-08-12 | 2011-07-28 | Nicola La Monica | Minigene |
| KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| WO2010129033A2 (en) * | 2009-04-29 | 2010-11-11 | Calmune Corporation | Modified antibodies for passive immunotherapy |
| BR122021025338B1 (pt) | 2009-11-24 | 2023-03-14 | Medimmune Limited | Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos |
| US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| WO2012027379A2 (en) | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| CA2902415C (en) | 2012-03-19 | 2024-02-06 | Stemline Therapeutics, Inc. | Methods for treating and monitoring the status of cancer |
| WO2013148147A1 (en) | 2012-03-26 | 2013-10-03 | The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| RS62406B1 (sr) | 2012-05-16 | 2021-10-29 | Stemline Therapeutics Inc | Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera |
| JP6345688B2 (ja) | 2012-12-05 | 2018-06-20 | ソラ・バイオサイエンシズ・エルエルシー | タンパク質発現増強ポリペプチド |
| CA2893918C (en) | 2012-12-06 | 2020-11-24 | Callaghan Innovation Research Limited | Conjugate compounds |
| KR20160016725A (ko) * | 2014-08-05 | 2016-02-15 | 주식회사 유영제약 | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| EP3464630A1 (en) | 2016-05-23 | 2019-04-10 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Methods of diagnosing cancer using cancer testis antigens |
| US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| KR20200067862A (ko) | 2017-10-09 | 2020-06-12 | 엔터롬 에스.에이. | 종양-관련된 항원 에피토프의 미생물 서열 변이체 |
| WO2019197563A2 (en) | 2018-04-11 | 2019-10-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
| BR112020020780A2 (pt) | 2018-04-11 | 2021-03-02 | Enterome S.A. | peptídeos antigênicos para prevenção e tratamento do câncer |
| MX2022004598A (es) | 2019-10-16 | 2022-09-23 | Enterome S A | Compuestos inmunogenicos para el tratamiento del cancer suprarrenal. |
| DK4021487T3 (da) | 2019-11-15 | 2024-02-12 | Enterome S A | Antigene peptider til forebyggelse og behandling af b-celle malignitet |
-
2017
- 2017-10-09 AU AU2017339577A patent/AU2017339577B2/en active Active
- 2017-10-09 EP EP17787365.0A patent/EP3522915A2/en active Pending
- 2017-10-09 CN CN201780074774.0A patent/CN110022893B/zh active Active
- 2017-10-09 KR KR1020247000094A patent/KR20240007316A/ko not_active Application Discontinuation
- 2017-10-09 JP JP2019519252A patent/JP7116278B2/ja active Active
- 2017-10-09 US US16/338,953 patent/US11478537B2/en active Active
- 2017-10-09 IL IL296165A patent/IL296165B2/en unknown
- 2017-10-09 KR KR1020197012112A patent/KR102622188B1/ko active IP Right Grant
- 2017-10-09 CN CN202311807705.XA patent/CN117801066A/zh active Pending
- 2017-10-09 CA CA3039322A patent/CA3039322A1/en active Pending
- 2017-10-09 IL IL302345A patent/IL302345A/en unknown
- 2017-10-09 WO PCT/EP2017/075673 patent/WO2018065623A2/en unknown
-
2019
- 2019-04-01 IL IL265751A patent/IL265751B2/en unknown
-
2022
- 2022-02-10 AU AU2022200872A patent/AU2022200872B2/en active Active
- 2022-06-15 JP JP2022096260A patent/JP7331207B2/ja active Active
- 2022-08-30 US US17/823,117 patent/US20230201322A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129666A patent/JP2023156414A/ja active Pending
- 2023-09-01 AU AU2023222999A patent/AU2023222999A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538183A5 (ja) | ||
| JP2015096070A5 (ja) | ||
| JP2017006120A5 (ja) | ||
| JP2013507907A5 (ja) | ||
| JP2017532966A5 (ja) | ||
| JP2008525033A5 (ja) | ||
| JP2018518457A5 (ja) | ||
| JP2014500724A5 (ja) | ||
| JP2008530975A5 (ja) | ||
| JP2010166916A5 (ja) | ||
| JP2015513897A5 (ja) | ||
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| JP2012115277A5 (ja) | ||
| JP2013506411A5 (ja) | ||
| JP2015514132A5 (ja) | ||
| JP2013172743A5 (ja) | ||
| JP2012529293A5 (ja) | ||
| JP2015522264A5 (ja) | ||
| JP2014507146A5 (ja) | ||
| JP2012515557A5 (ja) | ||
| JP2019537562A5 (ja) | ||
| JP2019534884A5 (ja) | ||
| JP2013537404A5 (ja) |